Biopeople

NetScientific nets biotech stalwart

NetScientific nets biotech stalwart

12.05.2015 - London-based Biomedical and healthcare technology group NetScientific has announced the appointment of biotech stalwart François Regis Martelet as its new CEO and Board Director. He will join the Group on 8 June taking over from Sir Richard Sykes, who will revert to his position as Non-Executive Chairman.

From April 2013 – October 2014, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. Prior to SVP, he was CEO at Topotarget A/S, a publicly traded European biotech company specialising in oncology therapeutics, which François successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit. He also headed US-based biotech Avax Technologies Inc. as CEO, which focuses on therapeutic oncology vaccines. During François’ rich and long career, he has also held several senior commercial positions at Merck & Co, Inc, Novartis Pharma, Schering-Plough and Eli Lily. François holds a PhD in Medicine and a Masters degree in Business.

http://www.european-biotechnology-news.com/people/bio-people/2015/francois-regis-martelet.html

29.01.2015 MedDay Pharmaceuticals has appointed Philippe Goupit as an independent Non-Executive Director on its board of directors. Mr Goupit brings his significant business and corporate development experience in the biotech and pharma sector to the Parisian-based company, which focuses on the treatment of nervous system disorders.

© MedDay Pharmaceuticals

Philippe, a pharma VIP has over 30 years’ experience in the industry, and has spent 20 years at Sanofi. Until recently he was Vice President, Corporate Licenses at Sanofi. His experience in business development covers M&A, as former head of the corporate M&A group in Sanofi, and licensing activities. Philippe has also served for some years as the Head of Investor Relations at Sanofi.

“Philippe’s broad experience will be hugely beneficial to MedDay as the Company continues to develop its pipeline of assets which address areas of unmet need in neurological and psychiatric diseases, through brain metabolism. Through his experience Philippe will contribute to MedDay’s corporate and business development strategy.”

27.01.2015 On 1 January, Ulla Ruotsalainen was appointed by the board of the TYY Foundation as Vice President of research activities at Tampere University of Technology (TUT), where she will oversee the development of research activities at the university.

© Hovione

With her vast wealth of experience, Ulla has had a long career working for a research institution, the corporate world, a health care unit and the Academy of Finland. She has also served two terms as the Dean of the Faculty of Computing and Electrical Engineering and sat on the Academy of Finland’s Research Council for Natural Sciences and Engineering.

Ruotsalainen places a high value on international research collaboration that cuts across disciplinary boundaries. “The building blocks of a high-quality research environment are a supportive atmosphere that encourages the exploration of new avenues for research and up-to-date equipment,” she says.

Her appointment as Vice President will run until 31 December 2016.

23.01.2015 Filipe Gaspar has been appointed Vice President of Research and Development at the Portuguese pharmaceutical ingredient manufacturer Hovione.

© Hovione

The chemical engineer has worked at Hovione for the last eleven years, mostly in particle engineering, but most recently in a business development role. Gaspar is co-author and co-inventor of numerous publications, scientific presentations and patents.

“For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver,” commented Hovione CEO Guy Villax.

21.01.2015 Fredrik Lindgren is the new CEO and president of Swedish clinical stage drug development company Hansa Medical.

© Hansa Medical

He replaces Emanuel Björne, who has led the company since it was established and takes over the role of Corporate Development Director. Lindgren, who holds a law degree from Lund University, has previously held the position of CEO at Karo Bio and Biolin Scientific. He is chairman and member of the board of Prostalund, Larodan Fine Chemicals and Exini Diagnostics.

19.01.2015 Slovenian chemist Tina Trdan Lušin has been honoured with the Pregl Award for outstanding doctoral work, a price annually conferred by the National Institute of Chemistry Slovenia.

© Pliva

Lušin, a researcher at the Sandoz Development Center, studied pharmacogenetic aspects of metabolism and transport of selective estrogen receptor modulators. With her work, the award committee said, Lušin "established the reason for inter-individual variability in the response to selective estrogen receptor modulators and thereby gained new information for treatment, which could be used in clinical practice."

15.01.2015 On 15 December 2014 Moberg Pharma AB welcomed Jeff Vernimb as its new General Manager for its US operations. He also became a member of the Swedish pharmaceutical company’s Management Team.

© Moberg Pharma

With more than 25 years of experience in consumer health products marketing and sales across multi-national and smaller entrepreneurial businesses, Jeff will help increase the Stockholm-based company’s US business. Prior to joining Moberg, Jeff was Vice President of sales and a member of the senior management team with Insight Pharmaceuticals. In addition to his position at Insight, he has held senior level positions at Dynova Laboratories, Cardinal Health, Novartis Consumer and Pfizer/Warner Lambert.

“It is a pleasure to welcome Jeff to the Management Team at Moberg. I look forward to working together to continue driving the growth of our US business,” said Peter Wolpert, CEO of Moberg Pharma AB.

13.01.2014 French biopharma Pharnext has nominated pharmaceutical and biotechnology industry executive Michel de Rosen to its Board of Directors as it sets its sights on expanding the company’s new therapeutics development, both nationally and internationally.

© Pharnext

Michel de Rosen has a wealth of experience in the sector, holding various executive positions for nearly 25 years at Rhone-Poulenc, in particular its pharmaceutical subsidiary Rhone-Poulenc Rorer, now known as Sanofi. While at Rhone-Poulenc, from 1983 to 1999, Michel served as president and CEO of Pharmuka, Rhone-Poulenc Fibers and Polymers, and then Rhone-Poulenc in the US. Post Rhone-Poulenc, he was CEO of ViroPharma, which was bought by Shire in 2014. After 15 years in the States, Michel returned to France and has been CEO of Eutelsat Communications since 2009.

“Michel de Rosen’s nomination to our board falls within our wish to accelerate Pharnext’s development both in France and abroad. His international expertise will prove valuable to us in our development dynamics,” said Daniel Cohen, chairman and CEO of Pharnext.

06.01.2014 Belgian Biotech FlandersBio has appointed Erwin Blomsma as its new chairman to continue the development of the company’s new strategy, which it intends to roll out both locally and globally.

© Okapi

Erwin started his career after a post-doctoral study at the University of Leuven in Belgium at Janssen Pharmaceutica in 1996 as Technology Manager. In 2000, he co-founded a contract research organisation Crystallice, which was later absorbed by another CRO, Avantium Technologies, where he became VP Technology in 2001 and COO in 2004. In 2007, Dr Blomsma co-founded and became CEO of Okapi Sciences, a company focused on animal health. Okapi Sciences developed a healthy pipeline of veterinary drugs, one of which was licensed to Novartis Animal Health in 2013. Since March 2014, he has been the general manager of Aratana Therapeutics NV in Leuven and VP of Aratana Therapeutics Inc.

“I am honoured to take up the task to lead FlandersBio into a next stage of growth and expansion,” said Erwin. “We will fully continue to develop the synergies with micro-electronics, ICT, medical technology and novel industrial and food applications in this further growth.”

29.12.2014 Chemist-by-training Sue Harris has been appointed as a non-Executive Director on the board of Abcam plc, a UK-based biotech company.

© Abcam plc

Harris has over 30 years of experience in financial and commercial roles. She held senior executive roles at Marks & Spencer, Standard Life and most recently worked as Finance Director at Lloyds Banking Group. Sue is a Member of the Audit and Assurance Council of the Financial Reporting Council and previously was a Non-Executive Director on the Board of St. James’s Place and a Member of the Audit and Remuneration Committee of the British Bankers’ Association.

19.12.2014 Gil Beyen has been appointed independent director of Belgian biotech Novadip Biosciences, a spin-off from Louvain University and Saint-Luc University Hospital active in skeletal regenerative medicine.

© Novadip Biosciences

Beyen is currently CEO and chairman of Erytech Pharma. Before that he served as CEO of French biotech Tigenix, which he also co-founded. In this capacity, he led the development and regulatory approval of ChondroCelect, the first Advanced Therapy Medicinal Product in Europe. He was also instrumental in the listing of the company and the subsequent merger with Cellerix. Beyen holds an MSc in Bio-Engineering from the University of Leuven and obtained an MBA from the University of Chicago in 1990.

Vorherige Seite3/25Nächste Seite

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.20 EUR418.5%
  • FORMYCON27.70 EUR316.5%
  • 4SC4.65 EUR315.2%

FLOP

  • MOLOGEN4.92 EUR-53.7%
  • BIOFRONTERA2.30 EUR-28.6%
  • PAION2.51 EUR-22.8%

No liability assumed, Date: 25.05.2015

Current issue

All issues